MARKET

CLRPF

CLRPF

Clarity Pharmaceuticals Ltd
OTCPK
1.750
NaN%
Closed 09:30 03/18 EDT
OPEN
--
PREV CLOSE
1.750
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
6.18
52 WEEK LOW
1.650
MARKET CAP
562.37M
P/E (TTM)
-17.2754
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CLRPF last week (0310-0314)?
Weekly Report · 1d ago
Weekly Report: what happened at CLRPF last week (0303-0307)?
Weekly Report · 03/10 11:11
Weekly Report: what happened at CLRPF last week (0224-0228)?
Weekly Report · 03/03 11:10
Weekly Report: what happened at CLRPF last week (0217-0221)?
Weekly Report · 02/24 11:10
Weekly Report: what happened at CLRPF last week (0210-0214)?
Weekly Report · 02/17 11:08
Weekly Report: what happened at CLRPF last week (0203-0207)?
Weekly Report · 02/10 11:02
Weekly Report: what happened at CLRPF last week (0127-0131)?
Weekly Report · 02/03 11:06
Weekly Report: what happened at CLRPF last week (0120-0124)?
Weekly Report · 01/27 11:09
More
About CLRPF
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.

Webull offers Clarity Pharmaceuticals Ltd stock information, including OTCPK: CLRPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRPF stock methods without spending real money on the virtual paper trading platform.